Its estimated that around 1.5 million people in the UK are on weight loss medication, with many buying drugs like Mounjaro or Wegovy privately
Neeland, Linge, and Birkenfeld (2024), writing in Diabetes, Obesity and Metabolism , conclude that skeletal muscle changes with GLP-1 receptor agonist treatment appear adaptive: reductions in muscle volume are commensurate with what is expected given aging, disease status, and weight loss achieved, and improvements in insulin sensitivity and muscle fat infiltration likely contribute to improved muscle quality
Side effect differences Both exert their benefits by slowing gastric emptying and dampening appetite, but that mechanism also leads to gastrointestinal side effects for many users
Cheeks may appear deflated
When Palpitations Signal a Safety Concern Occasional heart flutter lasting seconds to minutes typically represents benign palpitations tied to GLP-1 adaptation